Progression of Disease Within 24 Months (POD24) is an Independent Prognostic Factor for Survival in Waldenström Macroglobulinemia
Clinical Lymphoma Myeloma and Leukemia · 2026-11 · 26 (11) · e1287-e1293
DOI: 10.1016/j.clml.2026.08.012 ↗Kurz gefasst
Fachartikel in der Zeitschrift Clinical Lymphoma Myeloma and Leukemia, 2026-11. Verfasst von Maria Gavriatopoulou und 13 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical Therapeutics, Alexandra General Hospital, National and Kapodistrian University of Athens, Athens, Greece. Electronic address: …. Hauptthemen laut MEDLINE: Waldenstrom Macroglobulinemia. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 23 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
INTRODUCTION: The prognostic significance of progression of disease within 24 months (POD24) is well-established in many lymphomas, but data in Waldenström Macroglobulinemia (WM) remain limited and constrained by the frontline regimen utilized. METHODS: This retrospective, single-center study enrolled consecutive, unselected newly-diagnosed WM (NDWM) patients who received frontline treatment with DRC between January 1, 2002 and September 15, 2021. Individuals without a progression event and a follow-up of less than 24 months were excluded. A landmark approach was utilized in order to evaluate the prognostic impact of POD24 in subsequent OS. RESULTS: A total of 206 NDWM patients were enrolled; median age 70 years, 123 (59.7%) males. POD24, occurring in 47 (22.8%) patients, was associated with inferior OS post the 24-month landmark (5-year OS 62.8% vs. 82.1% in non-POD24, P = .001), maintained when adjusting for R-IPSSWM scores (aHR = 1.65; 95% CI, 1.01-2.70; P = .044). When accounting for non-WM related death as a competing event, the cumulative incidence of WM-related mortality at 5 years was 21.6% and 7.1% between POD24 and non-POD24, respectively. POD24 maintained its prognostic significance when further adjusting for R-IPSSWM (aSHR = 1.88, 95%CI: 1.01-3.49, P = .048). CONCLUSION: POD24 seems to be a predictor of inferior survival in patients with NDWM treated frontline with DRC. Even when accounting for immortal time bias through landmark analysis and adjusting for baseline risk via the R-IPSSWM and competing risks, patients with POD24 demonstrated a significantly higher risk of mortality. These findings suggest that POD24 could represent a high-risk phenotype that may require tailored management.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Clinical Therapeutics, Alexandra General Hospital, National and Kapodistrian University of Athens, Athens, Greece. Electronic address: mgavria@med.uoa.gr.
- Department of Clinical Therapeutics, Alexandra General Hospital, National and Kapodistrian University of Athens, Athens, Greece.
- Department of Clinical Therapeutics, Alexandra General Hospital, National and Kapodistrian University of Athens, Athens, Greece; Department of Medicine, Korea University, Seoul, South Korea.
Zitieren
APA
Gavriatopoulou, M., Ntanasis-Stathopoulos, I., Filippatos, C., Malandrakis, P., Katsadouros, I., Boutsikos, P., Migkou, M., Kanellias, N., Eleutherakis-Papaiakovou, E., Theodorakakou, F., Solia, E., Terpos, E., Kastritis, E., & Dimopoulos, M. A. (2026). Progression of Disease Within 24 Months (POD24) is an Independent Prognostic Factor for Survival in Waldenström Macroglobulinemia. Clinical Lymphoma Myeloma and Leukemia, 26(11), e1287-e1293. https://doi.org/10.1016/j.clml.2026.08.012
Vancouver
Gavriatopoulou M, Ntanasis-Stathopoulos I, Filippatos C, Malandrakis P, Katsadouros I, Boutsikos P, et al. Progression of Disease Within 24 Months (POD24) is an Independent Prognostic Factor for Survival in Waldenström Macroglobulinemia. Clinical Lymphoma Myeloma and Leukemia. 2026;26(11):e1287-e1293. doi:10.1016/j.clml.2026.08.012
BibTeX
@article{Gavriatopoulou2026,
author = {Gavriatopoulou, Maria and Ntanasis-Stathopoulos, Ioannis and Filippatos, Charalampos and Malandrakis, Panagiotis and Katsadouros, Ilias and Boutsikos, Panagiotis and Migkou, Magdalini and Kanellias, Nikolaos and Eleutherakis-Papaiakovou, Evangelos and Theodorakakou, Foteini and Solia, Eirini and Terpos, Evangelos and Kastritis, Efstathios and Dimopoulos, Meletios A},
title = {Progression of Disease Within 24 Months (POD24) is an Independent Prognostic Factor for Survival in Waldenström Macroglobulinemia},
journal = {Clinical Lymphoma Myeloma and Leukemia},
year = {2026},
volume = {26},
number = {11},
pages = {e1287--e1293},
doi = {10.1016/j.clml.2026.08.012}
}
EUVIMED